Nupsala

We specialise in equine and small animal veterinary orthopaedic products and have particular expertise in the use of biological and non-biological intraarticular or intralesional medication. We are involved in industry research and product development and are continually adding to our portfolio of biologicals, medical devices, lasers and conventional drugs for the treatment of musculoskeletal disorders. Our expertise is highly valued in the industry and we are often asked to lecture either in-practice or at veterinary conferences. Rather than product promotion, these scientific lectures cover tissue engineering and give useful tips and guidelines that will help vets formulate their treatment strategies...

,stem cell therapy,platelet rich plasma,prp,irap,bone marrow aspirate concentrate,canine osteoarthritis,hyaluronic acid,equine tendon injuries,equine osteoarthritis,polyacrylamide hydrogels,canine stem cell therapy,canine prp,bone marrow aspiration training (canine & equine),tendon,ligament and joint injection training (canine & equine,biologics,and regenerative medicine

Nupsala operates in the Veterinary services industry.

Nupsala's revenue is 11m - 100m

Nupsala has 11 - 50 employees.